CG Oncology, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Christina Rossi

CG Oncology, Inc.’s own tally for this item (“Elect Director: Christina Rossi”): 67,531,501 for, 89,825 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or rem…”
Support: 99.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 28,865,680 for, 22,684 withheld.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Victor Tong, Jr.

CG Oncology, Inc.’s own tally for this item (“Elect Director: Victor Tong, Jr.”): 62,401,874 for, 5,219,452 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or rem…”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 27,685,863 for, 1,202,491 withheld, 10 abstained.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.

CG Oncology, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 65,894,959 for, 1,603,011 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 83 managers: 28,834,800 for, 30,727 against, 22,684 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 201 managers: 51,173,661 for, 1,139,047 against, 28 not voted, 9,388 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 83 managers: 131,311 for, 22,684 abstained, 28,693,254 1 year, 40,858 3 year, 104 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 192 managers: 1,447,203 for, 318 against, 28 not voted, 43,820,714 1 year, 481,499 3 year, 2,800 2 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment by the Audit Committee of the Board of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

CG Oncology, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 83,711,522 for, 4,103 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 28,865,680 for, 22,684 abstained.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.